MedTrace Logo

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

NCT04319081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2023-01-17

No results posted yet for this study

Summary

The main objective will be to evaluate the changes in the cognitive function in naive patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal Cognitive Assesment questionnaire (MOCA).

The secondary objectives will be: 1) To evaluate the levels of LDL-cholesterol changes from the beginning to the end of the study 2) To evaluate changes in Quality of Life among the EuroQol EQ-5D-3L questionnaire (it will also be associated to the cognitive function) 3) Assesment of direct costs in medications and outpatients consultations related with the health procedures.

Conditions

Interventions

DRUG

PCSK9 inhibitor

Patients are included after PCSK9 inhibitors prescription , at the first dispensation

Sponsors & Collaborators

  • Jose Seijas Amigo

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2022-12-31
Completion
2023-01-13

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04319081 on ClinicalTrials.gov